108 results about "Thyroid cancer" patented technology

The invention provides a thyroid cancer auxiliary diagnosis and metastasis risk prediction method based on deep learning, and relates to the technical field of artificial intelligence auxiliary medical treatment, and the method comprises the steps: extracting ultrasonic image multi-scale features through a self-adaptive neural architecture search network, combining clinical examination data, fusing diagnosis and treatment knowledge through a neural symbol inference device, and carrying out the prediction of the metastasis risk. Generating a knowledge enhancement feature map; constructing a feature propagation field by using a dynamic neural field network, solving a dynamic evolution equation, and generating a spatial-temporal feature field representing the dynamic change of focus features; constructing a tumor diffusion kinetic model by using an implicit neural representation network and a nerve ordinary differential equation network, calculating a transition probability based on an optimal transmission algorithm, solving an optimal control equation, and outputting a metastasis risk prediction result of each organ; the thyroid cancer diagnosis accuracy and metastasis risk prediction reliability can be effectively improved, and doctors can be assisted in accurate diagnosis and treatment.

The invention discloses a thyroid cancer analysis method and device based on real-time fluorescent quantitative PCR. The method comprises the following steps: acquiring to-be-analyzed data; determining sample exclusive threshold line data according to the to-be-analyzed data; calculating a corrected Ct value based on double inflection point dynamics according to the exclusive threshold line data of the sample so as to obtain a final corrected Ct value; and generating a detection result according to the final corrected Ct value. Through optimization processing of the curve fitting algorithm, the linear characteristic of the fluorescence amplification curve is remarkably improved, the interference of background noise on the result is reduced, and the calculation stability of the Ct value is improved.

Theranostic targeted ultrasonic blasting nano-bubbles, a preparation method therefor, and use thereof, wherein the nano-bubbles are the targeted drug-gene nano-bubbles miRNA / FTY720 / PFP@PEI-T7 NBs. The nano-bubbles can be used for preparing a thyroid ultrasound diagnostic agent or a drug for treating thyroid cancer.

The invention relates to the field of disease risk prediction models, and discloses a thyroid cancer metastasis risk prediction model and a construction method and application thereof. The construction method of the model comprises the following steps: S1, collecting and preprocessing a sample; s2, gene expression quantity detection; s3, data set division and standardization processing; s4, constructing a deep learning model; s5, performing model evaluation; and the biomarker group for detecting the gene expression quantity in the S2 is composed of RPS4Y1, PKHD1L1, CRABP1, KRT18P8, AGPAT4, CPQ, SLC26A7 and RBP4. The prediction model can be used as a clinical auxiliary diagnosis tool and is used for guiding operation range selection, postoperative follow-up visit strategy making and early intervention of high-risk patients, and the precise diagnosis and treatment level of thyroid cancer is improved.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The invention relates to the technical field of intelligent rehabilitation monitoring, in particular to a real-time sticking and pricking effect monitoring system for thyroid cancer postoperative neck and shoulder function rehabilitation, which comprises a vector sequence generation module, a convergence section construction module, a direction difference calculation module, a stable section screening module and an effect monitoring module. According to the method, continuous image frames are collected, a grid observation node shadow direction vector sequence is extracted, the shadow flow trend caused by skin surface microscopic deformation is captured, and the relative deviation between the static texture main direction and the dynamic shadow vector angle is used for representing the real-time coupling degree of the sticking structure and the skin texture. Stable continuous time slices are screened through differential variation amplitude to eliminate invalid vibration interference, numerical variance is counted and calculated based on direction difference sequence dispersion degree, dynamic stability depth quantitative evaluation of a target area is achieved, and an accurate quantitative index reflecting muscle skin movement coordination is provided. The defect that the micromechanics interaction state is difficult to perceive through macroscopic contour monitoring is overcome.

The invention discloses a thyroid cancer and lymph node accurate positioning system based on three-dimensional imaging, which relates to the technical field of medical image modeling, and comprises the following steps: acquiring two-dimensional images of a cross section and a coronal plane, preprocessing the acquired two-dimensional images, extracting image features of the preprocessed two-dimensional images, and constructing a three-dimensional model based on the image features. Evaluating and adjusting the constructed three-dimensional model, displaying the adjusted three-dimensional model by using a visual tool and providing an interaction tool, generating an electronic diagnosis report based on a three-dimensional model positioning result, storing the generated electronic diagnosis report to a hospital internal database, and performing encryption measures on the access authority of the hospital internal database. According to the thyroid gland and lymph gland positioning method, feature processing is performed based on the preprocessed image, the three-dimensional model is constructed based on the feature processing result, and the adjusted three-dimensional model is displayed by using the visual tool, so that the accuracy of thyroid gland and lymph gland positioning is improved, and the complexity of an operation and the risk of lymph gland omission are reduced.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention discloses a method for constructing a gene methylation diagnostic model for differentiated thyroid cancer (PTC). The method includes the following steps: S1, obtaining a test sample; S2, extracting and storing DNA from the test sample; S3, performing methylation analysis; S4, establishing a diagnostic model based on DNA methylation, where the model shows that patients with cg03596178, cg06033721, cg06688989, cg07209244, cg07485775, cg14484681, cg19979108, and cg20943461 are more likely to experience disease progression and are considered risk factors; S5, cross-validating and evaluating the performance to obtain the gene methylation diagnostic model. This model, by detecting and statistically analyzing specific methylation sites, can differentiate patients with recurrent or metastatic characteristics in differentiated thyroid cancer. The relevant model can assist in the clinical diagnosis and follow-up of thyroid patients.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

The invention provides a methylation marker combination for identifying and diagnosing benign and malignant thyroid nodules or diagnosing thyroid cancer. The methylation marker combination comprises methylation TSHR, NIS and TPO genes or fragments thereof. In addition, the invention further provides a thyroid cancer diagnosis product and device based on the methylation marker combination and application of the thyroid cancer diagnosis product and device in thyroid nodule benign and malignant identification and thyroid cancer diagnosis. Whether a thyroid tissue sample or a blood sample is taken as a detection object, the methylation marker combination can realize efficient and sensitive diagnosis of thyroid cancer, and especially has outstanding performance in early thyroid cancer diagnosis, so that the methylation marker combination has a good application prospect. And the kit has important clinical application value and practical significance for early screening and diagnosis of thyroid cancer.

The application discloses a thyroid cancer gene detection report intelligent risk assessment method, and relates to the technical field of biomedical information processing, and comprises the following steps: risk conclusion extraction is carried out on obtained multiple thyroid cancer gene detection reports, and the risk conclusion in each detection report is arranged in order of detection time, the time interval between adjacent detection reports is marked, and continuous risk change records are formed. Through time sequence processing and trend reversal identification, the application realizes dynamic analysis of risk assessment, can capture reversal signals in the early stage of risk increase, and improves the timeliness and reliability of risk identification. By setting a reference point and a risk control entrance, combining time interval insertion and detection frequency improvement, the application realizes adaptive correction and continuous updating of risk results, and enhances the real-time performance and safety of risk assessment.

This invention discloses a traditional Chinese medicine composition, preparation, and its application in the preparation of a drug for treating postoperative cancer-related fatigue in thyroid cancer patients. The traditional Chinese medicine composition comprises the following components in parts by weight: 30-50 parts raw Astragalus membranaceus, 5-20 parts stir-fried Atractylodes macrocephala, 5-20 parts Curculigo orchioides, 5-20 parts Epimedium brevicornu, 5-20 parts Prunella vulgaris, 5-20 parts Dendrobium nobile, and 5-20 parts Lycium barbarum. This invention combines raw Astragalus membranaceus, stir-fried Atractylodes macrocephala, Curculigo orchioides, Epimedium brevicornu, Prunella vulgaris, Dendrobium nobile, and Lycium barbarum. Through the rational combination of these raw materials, it can effectively improve immune function, relieve physical and mental fatigue, and improve the quality of life of postoperative thyroid cancer patients.

The invention relates to the technical field of medical image and artificial intelligence technology crossing, in particular to an intelligent auxiliary diagnosis method and system for a frozen section in a thyroid cancer operation. According to the technical scheme, the method comprises the following steps that a thyroid tissue intraoperative frozen section to be diagnosed is prepared, and the frozen section does not need to be dyed or subjected to section sealing treatment; and scanning the frozen section by using a terahertz near-field imaging system to obtain terahertz near-field image data of the frozen section. According to the method, the terahertz near-field imaging technology is adopted, the situation that cell nucleus morphology is difficult to observe due to ice crystal artifacts in a traditional frozen section is avoided, cancer cells are automatically recognized in combination with an AI model trained based on large-scale labeling data, and the objectivity and consistency of diagnosis are remarkably improved; meanwhile, the steps of dyeing and mounting are omitted, and rapid imaging and analysis are realized, so that the intraoperative diagnosis time is greatly shortened, and a generated visual contour report also provides visual decision support for pathologists.

The application discloses a series of derivatives based on natural product gelsemium methyl, pharmaceutically acceptable salts and preparation methods thereof. Bioactivity tests show that the compounds have the effect of inhibiting the proliferation of various tumor cells. The compounds can be used for the treatment of various cancers (including but not limited to gastric cancer, liver cancer, lung cancer, esophageal cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, nasopharyngeal cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer and skin cancer) as active pharmaceutical ingredients.

The present invention discloses a method for treating thyroid cancer using a radiolabeled cleavage-type Evans Blue degenerated fibroblast-activating protein inhibitor, said drug having excellent safety and tolerance in patients with thyroid cancer and having a very excellent therapeutic prospect in the treatment of thyroid cancer.

The application discloses a kind of information management method and related equipment for thyroid cancer postoperative iodine 131 treatment patient.It comprises: based on the treatment management data of patient, scheduling model is constructed with patient waiting time, medical interaction cost and isolation bed vacancy time as optimization target, and bed capacity constraint, clinical urgency constraint, radiation protection constraint and medical availability constraint are established;Based on the scheduling model and the constraint condition, the joint optimization of patient reservation admission batch, isolation bed allocation and medical communication task is carried out, and the treatment scheduling result is generated;In the case where patient temporary adjustment, bed state change or iodine 131 treatment preparation abnormality is monitored, the treatment scheduling result is dynamically rearranged, so as to execute patient reminder, treatment connection and follow-up management according to the treatment scheduling result after rearrangement.It can solve the problems of low efficiency of reservation and resource coordination, fragmented medical records and lack of dynamic tracking mechanism in traditional information management mode.

The application discloses a chaga acidic polysaccharide IOP-2 with anti-thyroid cancer activity and application thereof, and belongs to the field of biological medicines. The application adopts a method for extracting chaga polysaccharide by boiling water and precipitating chaga polysaccharide by ethanol, and combines DEAE cellulose column purification technology, and successfully realizes separation of chaga polysaccharide by using the principle that macromolecular polysaccharide is insoluble in organic solvents, and obtains chaga acidic polysaccharide IOP-2 with anti-thyroid cancer activity. The monosaccharide composition of the chaga acidic polysaccharide IOP-2 includes fucose 0.71%, rhamnose 3.33%, arabinose 2.18%, galactose 2.92%, glucose 80.59%, xylan 3.46% and mannose 6.81% in terms of molar percentage. The significant effect of the chaga acidic polysaccharide IOP-2 on anti-thyroid cancer is verified through in-vivo and in-vitro experiments, and a new treatment method is provided for clinical treatment of thyroid cancer.

The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and / or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.

According to the thyroid cancer typing system based on the double-flow network, an image acquisition and preprocessing module acquires thyroid nodule ultrasonic image data and preprocesses the thyroid nodule ultrasonic image data to obtain standard image data; the classification module obtains benign and malignant classification results through the first-stage network; the typing module obtains a thyroid cancer typing result through the second-stage network; the decision module judges the nodule state based on the benign and malignant classification result, and if the nodule state is judged to be benign, a benign result is output; and if the judgment result is malignant, inputting into a typing module. The method has the progressive logic conforming to clinical diagnosis of judging good and bad first and then determining and typing, adopts a staged progressive network architecture, and preferentially excludes a large number of benign cases through the first-stage network to reduce the distinguishing burden and complexity of the second-stage network, so that the network in each stage can focus on learning the specific task characteristics, and the network efficiency is improved. And moreover, multi-path parallel extraction of nodule multi-dimensional features is adopted for cross fusion for pathological subtype typing, so that the accuracy is high.

The drainage tube comprises a tightening belt, a base and a drainage tube body, the base is arranged in the middle of the tightening belt, the drainage tube body is fixed to the base, the base is divided into a bottom disc and a rotating disc, the bottom disc is fixed to the tightening belt, the rotating disc is of a square structure, and a channel is formed in the middle of the upper surface of the rotating disc. Threaded holes A are formed in the left side and the right side of the upper surface of the rotary disc, studs A are arranged at the bottoms of the channels, and the rotary disc is connected with the base plate through the studs A. Fixing pieces are arranged on the left side and the right side, close to the conical pipe opening, of the drainage pipe, threaded holes B are formed in the middles of the fixing pieces, the threaded holes A correspond to the threaded holes B, and the fixing pieces penetrate through the threaded holes A and the threaded holes B through the studs B. The rotating disc is fixed on the rotating disc; the drainage tube fixing device is simple in structure, the base is fixed to the neck of a patient through the tightening belt, the drainage tube is further fixed to the base, and therefore it is guaranteed that the drainage tube cannot move or even fall off.

The invention discloses a thyroid cancer postoperative drainage device. The thyroid cancer postoperative drainage device comprises a double-cavity tube and a fixing mechanism. The double-cavity tube comprises a flushing tube and a drainage tube which are arranged side by side, the pipe diameter of the flushing tube is smaller than that of the drainage tube, the head end of the flushing tube is shorter than that of the drainage tube, and the double-cavity tube is sleeved with an inflatable and deflatable air bag. The fixing mechanism comprises a limiting seat, a fixing belt, a pressing plate and a manual adjusting part, the limiting seat is fixed to the human body through the fixing belt, a pipe penetrating groove is formed in the limiting seat, the double-cavity pipe penetrates through the pipe penetrating groove, the air bag is located in the pipe penetrating groove, and the pressing plate is movably arranged in the pipe penetrating groove and connected with the manual adjusting part. The manual adjusting piece is used for driving the pressing plate to move, and the air bag is extruded to be elastically deformed so that the double-cavity tube can be locked at the preset position in the tube penetrating groove. Through cooperation of the air bag and the pressing plate, lossless and accurate-positioning stable fixing of the drainage tube is achieved, the risk that the tube is displaced, disengaged or squashed is effectively avoided, and the safety and convenience of postoperative drainage are improved.

The invention belongs to the technical field of biological medicines, and particularly relates to a drug-loaded vesicle for treating thyroid cancer as well as a preparation method and application of the drug-loaded vesicle. The drug-loaded vesicle comprises a vesicle, wherein a cavity of the vesicle is loaded with radioactive iodine; the membrane surface of the vesicle is modified with: a) a first single-chain antibody fragment capable of specifically binding to thyroglobulin; according to the present invention, after the intravenous injection, the drug-loaded vesicle can be enriched in the thyroid cancer lesion area of the RAIR-DTC patient, such that the cancer cell proliferation is inhibited while the radioactive iodine is continuously released so as to provide the long-term treatment effect;

The invention relates to the field of medical health, and provides a personalized low-iodine diet control system and control method based on artificial intelligence, a data management module collects patient basic information, an iodine content database, patient diet record data and patient examination data; the personalized low-iodine recommendation module generates a personalized low-iodine menu through a low-iodine diet algorithm according to the collected data, generates patient guidance suggestions and issues the patient guidance suggestions to the patient side; and the risk assessment and early warning module estimates the daily iodine intake of the patient according to the diet record data of the patient and the examination data of the patient, and performs risk assessment and early warning on the daily iodine intake of the patient in combination with the target daily iodine intake. According to the invention, personalized low-iodine diet control based on a food iodine content table, diet records and an intelligent algorithm can be realized for a patient subjected to radioiodine 131 treatment after a thyroid cancer total resection operation.

The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis.

The invention relates to the technical field of medical intelligent informatization, and discloses a thyroid cancer electronic medical record processing method and system based on multi-modal data, and the method comprises the steps: obtaining a thyroid image and an associated electronic medical record text containing lesion position description; extracting a text orientation semantic vector representing a relative spatial relationship from the text, and extracting a focus morphology feature vector representing a visual morphology and an image spatial relationship vector representing a spatial position relative to a preset anatomical structure from the image; respectively calculating an orientation semantic consistency score and a morphological neighborhood consistency score, and fusing to obtain a comprehensive consistency score; and finally, comparing the comprehensive consistency score with a preset threshold value to determine whether the text description corresponds to the focus in the image. According to the method, cross-modal accurate matching is realized, the diagnosis and treatment data utilization rate and the judgment accuracy are improved, the high efficiency and accuracy requirements of clinical diagnosis and treatment are met, and meanwhile, the method is adaptive to a medical teaching scene.

The embodiment of the invention discloses an intelligent central control terminal control method, device and equipment based on a multi-mode large model. A specific embodiment of the method comprises the following steps: performing node fusion processing on an electronic medical record of a user and a thyroid cancer knowledge graph; performing feature node mapping processing on the user electronic medical record to obtain a user knowledge sub-graph; performing node attention aggregation processing on the user knowledge sub-graphs to obtain node feature information of each meta path sub-graph and each sub-graph; performing gating enhancement processing on the user electronic medical record, each meta path sub-graph and each sub-graph node feature information to obtain user feature information; performing scheme matching and adaptive optimization processing on the user feature information to obtain a target follow-up visit scheme; and controlling the intelligent central control terminal to execute the task auxiliary operation. According to the embodiment, interaction steps needing to be executed by the user can be reduced, and the operation convenience when the user controls the intelligent central control terminal to conduct rehabilitation training is improved.

The present technology relates to methods for determining whether a patient having thyroid nodules with indeterminate cytology will benefit from diagnostic surgery, e.g., lobectomy. These methods are based on screening a patient's thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to a specific set of thyroid cancer-related genes. Kits for use in practicing the methods are also provided.

The application discloses a method for detecting thyroid cancer driving gene mutations based on multiplex fluorescence PCR, and belongs to the technical field of molecular biology detection. The method simultaneously detects nine mutation sites, namely BRAF V600E, NRAS Q61R, NRAS Q61K, HRAS Q61R, HRAS Q61K, KRAS G12V, KRAS G12D, TERT C228T and TERT C250T in a single tube reaction. The method enhances the distinguishing ability of wild type and mutant types by using a locked nucleic acid modified allele-specific primer, suppresses wild type amplification by using a peptide nucleic acid clamp, introduces a competitive internal reference probe to correct amplification efficiency difference, and reduces the sample usage to one fifth of that of a traditional multi-tube scheme. The mutation detection lower limit reaches 0.5% allele frequency, and the total time consumption is not more than 2.5 h.

To provide a new compound having thyroid stimulating hormone receptor antagonist activity and useful for treating thyroid-related diseases.SOLUTION: The present invention relates to a bicyclo [1.1.1] pentane compound represented by the following formula (I) or a pharmacologically acceptable salt thereof. Since the compound of the present invention or a pharmaceutically acceptable salt thereof has an antagonist activity against a thyroid stimulating hormone receptor, it is useful as a therapeutic agent for thyroid-related diseases (e.g., hyperthyroidism, Graves' disease, thyroid ophthalmopathy and thyroid cancer) and the like.SELECTED DRAWING: None